March 01, 2018

 

Journal highlights February

In our regular feature, Editor-in-Chief Arnold von Eckardstein highlights interesting articles from recent issues of Atherosclerosis journal.

The February issue 269 of Atherosclerosis contains several articles that illustrate how the advance of technology in molecular genetics helps deepen insights into the pathogenesis and clinical manifestation of classical monogenic dyslipidemias, unravels novel genetic determinants of atherosclerotic vascular disease, or opens avenues to novel mechanisms of regulation.

To the journal highlights February >>
To the February issue of Atherosclerosis >>

Of potential interest to our members:

Announcing PCSK9 Competitive Grant Program

An independently-reviewed competitive grant program supported by Amgen to fund innovative research advancing the understanding of PCSK9 and atherosclerosis.

PCSK9 Competitive Grant Program

Amgen is delighted to announce the launch of the PCSK9 Competitive Grant Program, which will provide an opportunity for investigators from around the world to compete for individual grants of up to $200,000 USD for novel research proposals that seek to advance the understanding of PCSK9 and atherosclerosis.

The program is global in reach and is open to proposals from established and junior investigators.The PCSK9 Competitive Grant Program aims to advance the science of PCSK9, especially at the junction with atherosclerosis and atherosclerosis-related mechanisms.

The deadline for applications is Friday, May 11, 2018.

Read more and apply >>

Last day for application:

EAS Advanced Course on FH - Familial Hypercholesterolaemia
Debrecen, Hungary



This 3-day course is organised by EAS and the Hungarian Atherosclerosis Society.

The Course is intended for physicians (specialists or in specialist training), senior PhD students and PhDs that are involved in the screening and treatment of familial hypercholesterolemia (H).

The Course aims to provide up-to-date information about the epidemiology and pathomechanism as well as the screening, diagnostic and the latest therapeutic options in FH with a special emphasis on the Eastern European region. Case presentations related to FH, other lipid abnormalities, diagnostic and therapeutic challenges will provide further insight on everyday practice. Special challenges as statin intolerance, LDL apheresis, FH treatment in children and pregnancy will also be addressed.

Attending EAS Advanced Courses requires an active individual EAS Membership.
Application open until March 01, 2018.

Read more about the Course and how to apply >>
To the preliminary programme >>
Read more about EAS membership >>

Abstract submission open:

The 41st Scientific meeting of the ELC will be held at the Evangelische Akademie in Tutzing, Germany, from September 10-13, 2018.

The overall aim of the ELC meeting is to bring researchers together within the field of lipoproteins in relation, but not limited, to cardiometabolic disease. The ELC meeting is a relatively small informal meeting that can be attended by only approx. 110 participants. The registration fees are low (€200-400 depending on age), and include participation in the scientific sessions, accommodation and all meals.

The concept is a good mix of presentations by research investigators, postdocs and graduate students. Abstracts are selected according to their scientific merit, and it has become one of the traditions that many graduate students give presentations. Young investigators automatically participate in the competition for Young Investigator Oral and Poster Awards, which include a financial reward.

We look forward to meet you in wonderful Tutzing at the Evangelische Akademie in Tutzing, Bavaria, Germany! To be able to be selected to attend this year’s meeting, please make sure to submit your abstract by May 01, 2018.

To the 41st ELC Scientific meeting >>
Scientific programme >>
Important to know before abstract submission >>
Abstract submission - Step-by-Step >>

 

Find out more

About EAS

EAS Membership

EAS Congress

EAS Educational Initiatives

EAS Publications

European Lipoprotein Club (ELC)

EAS-FH Studies Collaboration (FHSC)

Visit: eas-society.org

About this email

You have received this email because you are currently subscribed to receive general correspondence from EAS.

  

European Atherosclerosis Society
Mässans Gata 18
Box 5243
SE-402 24, Gothenburg SWEDEN

Organisation number: 802418-0427

This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@

 

European Atherosclerosis Society © 2018